A product which employs nanotechnology to deliver oral CBD products is set to begin over the counter U.S. sales, according to a Times of Israel report. The nanotech delivery system employed by Hygia Products is owned by Israel startup Lyotropic Delivery Systems Biotech. The CBD product is being marketed in the states by Delaware-based Ananda Scientific as a nutraceutical rather than a medication, making it available without a prescription.
The technology was designed by Hebrew University of Jerusalem Professor Nissim Garti and licensed to LDS Biotech through Yissum, the technology transfer company of the university. Ananda Scientific and LDS Biotech entered into the licensing agreement in 2015, which allows Ananda to use the delivery technology.
The nanotech formulations are able to remain stable for long periods of time without release or breakdown of the bioactive material, making it an attractive product for potential retailers.
“We have developed nano-droplets that absorb on their interface only the CBD compound from the cannabis, and not the THC,” Garti said in the report. “Unlike other CBD formulations that are available on the market and are dispersed in oil, our product is better and more quickly absorbed by the body. Our CBD formulation is also protected from being transformed, after it is ingested, into THC which is a risk factor in other existing products.”
The products are available in a variety of forms including drops and liquid forms that can be dissolved in water.